Satellos Bioscience Inc.
MSLE Nasdaq Pharmaceutical Preparations Financials FY2024–FY2025
What Satellos Bioscience Inc. does
No business description yet.
- Legal name
- Satellos Bioscience Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 40-F · Mar 27, 2026
- Accession · CIK
- 0001104659-26-035729
0001421642
Revenue and margins
Satellos Bioscience Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$23.6M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Satellos Bioscience Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 52.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Satellos Bioscience Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $40.1M | $9.8M |
| Current ratio | 14.2x | 7.8x |
| Quick ratio | 14.2x | 7.8x |
| Total assets | $50.7M | $31.9M |
| Total liabilities | $3.6M | $4.1M |
| Shareholders' equity | $47.2M | $27.8M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | −4.7% | −3.1% |
| Altman Z'' | 13.55 | −1.13 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $14.4M | $18.4M |
| Operating income | −$20.4M | −$26.5M |
| Pretax income | −$20.6M | −$24.7M |
| Income tax | — | $0.2M |
| Net income | −$20.6M | −$24.9M |
| Diluted EPS | −$2.16 | −$1.70 |
| Diluted shares | 0.01B | 0.01B |
| Cash flow | ||
| Cash from operations | −$18.3M | −$23.6M |
| Capital expenditure | $0.0M | $0.0M |
| Free cash flow | −$18.3M | −$23.6M |
| Stock-based compensation | $1.6M | $3.2M |
| Balance sheet | ||
| Cash and short-term investments | $40.1M | $9.8M |
| Current assets | $50.7M | $31.9M |
| Current liabilities | $3.6M | $4.1M |
| Property and equipment, net | $0.0M | $0.0M |
| Total assets | $50.7M | $31.9M |
| Total liabilities | $3.6M | $4.1M |
| Shareholders' equity | $47.2M | $27.8M |
| Returns | ||
| Return on capital employed | −43.2% | −95.2% |
| Return on equity | −43.7% | −66.4% |
| Return on assets | −40.7% | −60.2% |
| Return on tangible equity | −43.7% | −89.5% |
| Growth | ||
| Share count change | — | 52.6% |
| Financial health | ||
| Current ratio | 14.2x | 7.8x |
| Quick ratio | 14.2x | 7.8x |
| Quality scores | ||
| Altman Z'' | 13.5 | −1.1 |
| Accruals ratio | −4.7% | −3.1% |
Source: SEC EDGAR XBRL filings (CIK 0001421642). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.